Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRMT1 | Q99873 | 1/20 | 0.51 |
| ▸ | EPHX2 | P34913 | 6/20 | 0.51 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.49 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | FAAH | O00519 | 3/20 | 0.46 |
| ▸ | LTA4H | P09960 | 1/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | CNR1 | P21554 | 2/20 | 0.43 |
| ▸ | CNR2 | P34972 | 2/20 | 0.43 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.43 |
| ▸ | PLA2G10 | O15496 | 1/20 | 0.43 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.42 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13706976 | 0.97 | EPHX2 (0.54) | PRMT1EPHX2ADRA1ACYP1A2FAAH | |
| SCHEMBL12891252 | 0.97 | EPHX2 (0.54) | PRMT1EPHX2ADRA1ACYP1A2FAAH | |
| SCHEMBL16944361 | 0.97 | EPHX2 (0.54) | PRMT1EPHX2ADRA1ACYP1A2FAAH | |
| SCHEMBL13706974 | 0.97 | EPHX2 (0.54) | PRMT1EPHX2ADRA1ACYP1A2FAAH | |
| SCHEMBL12891255 | 0.97 | EPHX2 (0.54) | PRMT1EPHX2ADRA1ACYP1A2FAAH | |
| SCHEMBL12666256 | 0.97 | EPHX2 (0.54) | PRMT1EPHX2ADRA1ACYP1A2FAAH | |
| SCHEMBL13706958 | 0.95 | EPHX2 (0.52) | PRMT1EPHX2ADRA1ACYP1A2FAAH | |
| SCHEMBL13706990 | 0.95 | EPHX2 (0.52) | PRMT1EPHX2ADRA1ACYP1A2FAAH | |
| SCHEMBL13706991 | 0.95 | EPHX2 (0.52) | PRMT1EPHX2ADRA1ACYP1A2FAAH | |
| SCHEMBL13706988 | 0.95 | EPHX2 (0.52) | PRMT1EPHX2ADRA1ACYP1A2FAAH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8933021-B2 | Insulin derivative | NOVO NORDISK A/S (DK) | 2015-01-13 | — | — | US | disclosed |
| US-20090239785-A1 | Insulin Derivative | NOVO NORDISK A/S (DK) | 2009-09-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090239785-A1 | Insulin Derivative | IAPP, INSR, GPR119 | PRMT1 2846/4885EPHX2 3897/4885ADRA1A 3042/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.